TITLE

What role does imatinib play in CML after the approval of dasatinib and nilotinib for newly diagnosed CML?

AUTHOR(S)
Talpaz, Moshe; Deininger, Michael
PUB. DATE
February 2011
SOURCE
Hem/Onc Today;2/25/2011, Vol. 12 Issue 4, p11
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article presents the views of U.S. medical experts Moshe Talpaz and Michael Deininger on the role that imatinib and nilotinib play in the treatment of newly diagnosed chronic myelogenous leukemia (CML).
ACCESSION #
62393618

 

Related Articles

  • IN THIS ISSUE.  // JNCI: Journal of the National Cancer Institute;Apr2011, Vol. 103 Issue 7, p525 

    The article discusses the various reports published in the April 6, 2011 issue of the "Journal of the National Cancer Institute" which include "Long Term Effects of Imatinib in Chronic Myeloid Leukemia," "Sex Hormones and Breast Cancer" and "Retinoic Acid Signaling in Glioblastoma."

  • DAISION: Updated data further supports dasatinib over imatinib.  // Hem/Onc Today;1/25/2011, Vol. 12 Issue 2, p18 

    The article discusses research being done on the superiority of dasatinib in producing cytogenic response and molecular response over imatinib for patients with chronic myeloid leukemia.

  • Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Fiorini Furtado, Vanessa; Rengel Santos, Gustavo; Siqueira de Carvalho, Denise; Vinícius Staziaki, Pedro; Pasquini, Ricardo; Moreira Funfee, Vaneuza Araújo // Revista Brasileira de Hematologia e Hemoterapia;Sep/Oct2015, Vol. 37 Issue 5, p341 

    Background: Published criteria defining the accelerated phase in chronic myeloid leukemia are heterogeneous and little is known about predictors of poor outcome. Methods: This is a retrospective study of 139 subjects in the accelerated phase of chronic myeloid leukemia treated with imatinib at a...

  • Nilotinib linked to fewer BCR-ABL mutations in chronic phase CML. Adams, Stacey L.; Leiser, Mark; Shafer, Emily; Taliercio, Adam; Volansky, Rob // Hem/Onc Today;4/25/2013, Vol. 14 Issue 8, p44 

    The article discusses the results of a study which showed a link between nilotinib and fewer treatment-emergent breakpoint cluster region-abelson (BCR-ABL) mutations than imatinib in chronic myeloid leukemia treatment and reduced rates of progression to accelerated phase.

  • Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist. Zhang, M; Luo, Z; Liu, H; Croce, C M; Burke, T R; Bottaro, D P // Leukemia (08876924);Apr2014, Vol. 28 Issue 4, p948 

    A letter to the editor is presented regarding a study of the synergistic enhancement of K562 leukemia cell proliferation by imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist, focusing on its association with ell cycle arrest, and induction of apoptosis.

  • Imatinib/nilotinib.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p116 

    The article presents a case study of a 54-year-old man who was diagnosed with neutropenia and drug resistance in chronic myeloid leukaemia (CML) following administration of imatinib and nilotinib.

  • Imatinib.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p113 

    The article presents a case study of a 60-year-old woman who was diagnosed with extensive hyperpigmentation following administration of imatinib for chronic myeloid leukemia.

  • Imatinib.  // Reactions Weekly;Nov2015, Vol. 1578 Issue 1, p164 

    The article presents case studies of two children with chronic phase chronic myeloid leukaemia who developed various toxicities during treatment with imatinib.

  • Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors. Minami, Y; Abe, A; Minami, M; Kitamura, K; Hiraga, J; Mizuno, S; Ymamoto, K; Sawa, M; Inagaki, Y; Miyamura, K; Naoe, T // Leukemia (08876924);Sep2012, Vol. 26 Issue 9, p2142 

    A letter to the editor is presented in response to the article regarding the study of CD34+ chronic myeloid leukemia (CML) stem/progenitor cells retention during imatinib treatment and rapid reduction following second-generation BCR-ABL inhibitors treatment.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics